Dane Leone
Stock Analyst at Raymond James
(1.62)
# 3,222
Out of 4,761 analysts
88
Total ratings
38.24%
Success rate
-5.72%
Average return
Main Sectors:
Stocks Rated by Dane Leone
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.93 | +330.11% | 3 | Nov 8, 2024 | |
RGNX REGENXBIO | Reinstates: Outperform | $45 | $7.27 | +518.98% | 2 | Feb 21, 2024 | |
BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $92.25 | +8.40% | 9 | Dec 22, 2023 | |
RVMD Revolution Medicines | Initiates: Outperform | $30 | $41.34 | -27.43% | 1 | Nov 16, 2023 | |
BLUE bluebird bio | Maintains: Outperform | $200 → $260 | $4.08 | +6,272.55% | 6 | Nov 8, 2023 | |
REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $700.33 | +35.65% | 10 | Nov 3, 2023 | |
NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.05 | +534.15% | 5 | Oct 18, 2023 | |
BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $36.85 | +24.83% | 2 | Jul 18, 2023 | |
GLPG Galapagos NV | Upgrades: Outperform | $69 | $26.74 | +158.04% | 5 | May 8, 2023 | |
RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $3.92 | +639.80% | 2 | Apr 19, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $8 | $2.92 | +173.97% | 2 | Nov 10, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $29 → $14 | $7.00 | +100.00% | 5 | Nov 8, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $15.74 | +268.49% | 4 | Oct 13, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $31.77 | +120.33% | 3 | Aug 29, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.17 | - | 6 | Aug 10, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $50.26 | +25.35% | 2 | Aug 5, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $55.83 | - | 4 | Jun 6, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.10 | - | 2 | Apr 5, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $47.84 | +35.87% | 3 | Oct 8, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.31 | - | 5 | Dec 1, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $303.01 | -15.84% | 3 | Oct 26, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $4.22 | +658.29% | 2 | Sep 10, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $162.30 | - | 2 | Jul 21, 2017 |
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.93
Upside: +330.11%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $7.27
Upside: +518.98%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $92.25
Upside: +8.40%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $41.34
Upside: -27.43%
bluebird bio
Nov 8, 2023
Maintains: Outperform
Price Target: $200 → $260
Current: $4.08
Upside: +6,272.55%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $700.33
Upside: +35.65%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.05
Upside: +534.15%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $36.85
Upside: +24.83%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $26.74
Upside: +158.04%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $3.92
Upside: +639.80%
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $2.92
Upside: +173.97%
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $7.00
Upside: +100.00%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $15.74
Upside: +268.49%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $31.77
Upside: +120.33%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.17
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $50.26
Upside: +25.35%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $55.83
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.10
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $47.84
Upside: +35.87%
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $7.31
Upside: -
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $303.01
Upside: -15.84%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $4.22
Upside: +658.29%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $162.30
Upside: -